STOCK TITAN

[Form 4] ASP Isotopes Inc. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Moore Duncan, a director of ASP Isotopes Inc. (ASPI), reported the sale of 75,000 shares on 08/29/2025 at a weighted average price of $9.2831. After the sale he beneficially owned 994,553 shares. The filing states the sale included shares sold to satisfy income tax liabilities arising from the vesting of a previously granted restricted stock award for 200,000 shares. The weighted-average price represents multiple trades executed between $8.95 and $10.20. The Form 4 was signed by an attorney-in-fact on 09/03/2025. This disclosure records an insider disposition tied to tax withholding for a stock award.

Moore Duncan, membro del consiglio di ASP Isotopes Inc. (ASPI), ha comunicato la vendita di 75,000 azioni effettuata il 08/29/2025 a un prezzo medio ponderato di $9.2831. Dopo la cessione risultava titolare beneficiario di 994,553 azioni. La comunicazione specifica che la vendita includeva azioni cedute per coprire imposte sul reddito derivanti dalla maturazione di un precedente premio in azioni ristrette pari a 200,000 azioni. Il prezzo medio ponderato riflette operazioni multiple eseguite tra $8.95 e $10.20. Il Modulo 4 è stato firmato da un procuratore il 09/03/2025. Si tratta di una comunicazione di disposizione da parte di un insider correlata alla ritenuta fiscale su un premio azionario.

Moore Duncan, director de ASP Isotopes Inc. (ASPI), informó la venta de 75,000 acciones el 08/29/2025 a un precio promedio ponderado de $9.2831. Tras la venta, poseía beneficiosamente 994,553 acciones. La presentación indica que la operación incluyó acciones vendidas para cubrir obligaciones fiscales derivadas del otorgamiento de una concesión anterior de acciones restringidas por 200,000 acciones. El precio promedio ponderado corresponde a varias transacciones ejecutadas entre $8.95 y $10.20. El Formulario 4 fue firmado por un apoderado el 09/03/2025. Esta divulgación registra una disposición de un insider vinculada a la retención fiscal por un premio en acciones.

Moore Duncan, ASP Isotopes Inc.(ASPI) 이사의 경우, 08/29/202575,000주를 가중평균 가격 $9.2831에 매도했다고 보고했습니다. 매도 후 해당 임원은 994,553주를 실질적으로 보유하고 있었습니다. 제출서류에는 이번 매도에 이전에 부여된 제한주 보상의 취득으로 발생한 소득세 납부를 위해 주식이 매각되었다고 기재되어 있으며, 이 제한주 보상은 200,000주였습니다. 가중평균 가격은 $8.95~$10.20 사이에서 체결된 여러 거래를 반영합니다. Form 4는 09/03/2025에 대리인이 서명했습니다. 이는 주식 보상에 대한 세금 원천징수와 관련된 내부자 처분 공시입니다.

Moore Duncan, administrateur d'ASP Isotopes Inc. (ASPI), a déclaré la vente de 75,000 actions le 08/29/2025 à un prix moyen pondéré de $9.2831. Après la cession, il détenait bénéficiairement 994,553 actions. Le dossier indique que la vente comprenait des actions cédées pour couvrir des impôts sur le revenu liés à la levée d'une attribution d'actions restreintes précédemment accordée, portant sur 200,000 actions. Le prix moyen pondéré reflète plusieurs opérations exécutées entre $8.95 et $10.20. Le formulaire 4 a été signé par un mandataire le 09/03/2025. Cette déclaration enregistre une cession par un initié liée à la retenue fiscale d'une attribution d'actions.

Moore Duncan, Direktor von ASP Isotopes Inc. (ASPI), meldete den Verkauf von 75,000 Aktien am 08/29/2025 zu einem gewichteten Durchschnittspreis von $9.2831. Nach dem Verkauf hielt er wirtschaftlich 994,553 Aktien. Die Meldung gibt an, dass die Transaktion Aktien umfasste, die veräußert wurden, um Einkommensteuerverbindlichkeiten im Zusammenhang mit dem Zufluss einer zuvor gewährten Restricted-Stock-Zuteilung über 200,000 Aktien zu begleichen. Der gewichtete Durchschnittspreis ergibt sich aus mehreren Trades zwischen $8.95 und $10.20. Das Formular 4 wurde am 09/03/2025 von einem Bevollmächtigten unterschrieben. Diese Offenlegung dokumentiert eine Insider-Veräußerung im Zusammenhang mit Steuerabzügen für eine Aktienzuteilung.

Positive
  • Sale was disclosed and explained as tax-related due to vesting, providing transparency to investors
  • Reporting person retains substantial ownership with 994,553 shares reported after the transaction
Negative
  • Director disposed of 75,000 shares, reducing direct holdings
  • Vesting of 200,000 restricted shares created a tax liability requiring share sales

Insights

TL;DR: Insider sale was tax-driven and reduces direct holdings modestly; no indicated change in company guidance or operations.

The Form 4 documents a director-initiated sale of 75,000 shares at a weighted average of $9.2831, reducing reported beneficial ownership to 994,553 shares. The filing explicitly states the purpose was to satisfy income taxes from the vesting of 200,000 restricted shares. Such transactions are commonly administrative in nature and do not by themselves signal operational or financial changes at the company.

TL;DR: This is a routine, disclosed disposition tied to equity award vesting; documentation and signature by attorney-in-fact meet filing norms.

The disclosure identifies the reporting person as a director and shows the sale was executed on 08/29/2025 with footnotes clarifying price range and tax-related motive. The reporting and signature elements appear complete, including an attorney-in-fact signature dated 09/03/2025. From a governance standpoint, the filing provides required transparency about insider transactions related to compensation events.

Moore Duncan, membro del consiglio di ASP Isotopes Inc. (ASPI), ha comunicato la vendita di 75,000 azioni effettuata il 08/29/2025 a un prezzo medio ponderato di $9.2831. Dopo la cessione risultava titolare beneficiario di 994,553 azioni. La comunicazione specifica che la vendita includeva azioni cedute per coprire imposte sul reddito derivanti dalla maturazione di un precedente premio in azioni ristrette pari a 200,000 azioni. Il prezzo medio ponderato riflette operazioni multiple eseguite tra $8.95 e $10.20. Il Modulo 4 è stato firmato da un procuratore il 09/03/2025. Si tratta di una comunicazione di disposizione da parte di un insider correlata alla ritenuta fiscale su un premio azionario.

Moore Duncan, director de ASP Isotopes Inc. (ASPI), informó la venta de 75,000 acciones el 08/29/2025 a un precio promedio ponderado de $9.2831. Tras la venta, poseía beneficiosamente 994,553 acciones. La presentación indica que la operación incluyó acciones vendidas para cubrir obligaciones fiscales derivadas del otorgamiento de una concesión anterior de acciones restringidas por 200,000 acciones. El precio promedio ponderado corresponde a varias transacciones ejecutadas entre $8.95 y $10.20. El Formulario 4 fue firmado por un apoderado el 09/03/2025. Esta divulgación registra una disposición de un insider vinculada a la retención fiscal por un premio en acciones.

Moore Duncan, ASP Isotopes Inc.(ASPI) 이사의 경우, 08/29/202575,000주를 가중평균 가격 $9.2831에 매도했다고 보고했습니다. 매도 후 해당 임원은 994,553주를 실질적으로 보유하고 있었습니다. 제출서류에는 이번 매도에 이전에 부여된 제한주 보상의 취득으로 발생한 소득세 납부를 위해 주식이 매각되었다고 기재되어 있으며, 이 제한주 보상은 200,000주였습니다. 가중평균 가격은 $8.95~$10.20 사이에서 체결된 여러 거래를 반영합니다. Form 4는 09/03/2025에 대리인이 서명했습니다. 이는 주식 보상에 대한 세금 원천징수와 관련된 내부자 처분 공시입니다.

Moore Duncan, administrateur d'ASP Isotopes Inc. (ASPI), a déclaré la vente de 75,000 actions le 08/29/2025 à un prix moyen pondéré de $9.2831. Après la cession, il détenait bénéficiairement 994,553 actions. Le dossier indique que la vente comprenait des actions cédées pour couvrir des impôts sur le revenu liés à la levée d'une attribution d'actions restreintes précédemment accordée, portant sur 200,000 actions. Le prix moyen pondéré reflète plusieurs opérations exécutées entre $8.95 et $10.20. Le formulaire 4 a été signé par un mandataire le 09/03/2025. Cette déclaration enregistre une cession par un initié liée à la retenue fiscale d'une attribution d'actions.

Moore Duncan, Direktor von ASP Isotopes Inc. (ASPI), meldete den Verkauf von 75,000 Aktien am 08/29/2025 zu einem gewichteten Durchschnittspreis von $9.2831. Nach dem Verkauf hielt er wirtschaftlich 994,553 Aktien. Die Meldung gibt an, dass die Transaktion Aktien umfasste, die veräußert wurden, um Einkommensteuerverbindlichkeiten im Zusammenhang mit dem Zufluss einer zuvor gewährten Restricted-Stock-Zuteilung über 200,000 Aktien zu begleichen. Der gewichtete Durchschnittspreis ergibt sich aus mehreren Trades zwischen $8.95 und $10.20. Das Formular 4 wurde am 09/03/2025 von einem Bevollmächtigten unterschrieben. Diese Offenlegung dokumentiert eine Insider-Veräußerung im Zusammenhang mit Steuerabzügen für eine Aktienzuteilung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moore Duncan

(Last) (First) (Middle)
C/O ASP ISOTOPES INC.
601 PENNSYLVANIA AVENUE NW, SUITE 900

(Street)
WASHINGTON, DC DC 20004

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ASP Isotopes Inc. [ ASPI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/29/2025 S(1) 75,000 D $9.2831(2) 994,553 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale of shares reported in this Form 4 includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award for 200,000 shares pursuant to an issuer equity incentive plan.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.95 to $10.20, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2.
Remarks:
/s/ Donald Ainscow, as attorney-in-fact 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Moore Duncan report on Form 4 for ASPI?

The Form 4 reports the sale of 75,000 shares on 08/29/2025 at a weighted average price of $9.2831.

Why were shares sold according to the Form 4?

The filing states shares were sold to satisfy income tax liabilities resulting from the vesting of a restricted stock award for 200,000 shares.

How many ASPI shares did the reporting person own after the sale?

The reporting person beneficially owned 994,553 shares following the reported transaction.

What price range were the shares sold at?

The filing discloses the shares were sold in multiple transactions at prices ranging from $8.95 to $10.20.

Who signed the Form 4 and when?

The Form 4 was signed by Donald Ainscow, as attorney-in-fact, dated 09/03/2025.
ASP Isotopes

NASDAQ:ASPI

ASPI Rankings

ASPI Latest News

ASPI Latest SEC Filings

ASPI Stock Data

731.63M
71.24M
22.48%
45.31%
14.41%
Chemicals
Miscellaneous Chemical Products
Link
United States
WASHINGTON